Member Info for graking

TirickyDicky. Spot on.

TrekMadonna. Aren't you quoting production and profits on the basis if production profiling. All Ias ked was what has happened to exploration since the early July update? I did not ask for a repeat what we already know.

A 1400 RNS ? (2.00 pm) Implausible as markets in full swing. Lodged with SX soon after 7.00am

Another week and hopefully price will rise above 2500 and in same territory as a year ago. Just need another contract or two but they have limited skilled staff who need to see ongoing contracts started/completed. Now if Marks were to sell off its food business into a separate public quoted company and possibly retain 51% of the shares - wow !

Potnak - You have a strange way of converting test start dates of 2022 and licensing into your word "delayed". A word NOT used nor implied in the RNS even. but strangely you seem to like it Are you even aware that responsible pharma research does not rush in and follows statutory guidelines on both efficacy and safety prior to human trials. The current spate of so called succesful vaccines have been fast tracked and we shall all reap the crop in due course. In the meantime all other R&D HAS to follow guidelines. Do you get that ?

Just re-read it and whilst it is chirpy about production, my interest lies in their continuing to find good reserves. This last month of July was clearly disappointing as no mention of new findings unlike previous months.

Cannot see any serious investors being troubled by this. The old maxim applies - One swallow does not make a summer. But sounds like a driver or two with a grudge and the paper says it saw the wage slip with hours and pay shown . DID THEY SEE THE EMPLOYMENT CONTRACT. DOUBT IT. Undoubtedly Ocados investigation findings will never be reported by the press and to be honest, what delivery firm pays that sort of money in the knowledge that not only are they breaking the law but the drivers would leave en masse for the next delivery firm and claim constructive dismissal as well. the newspaper story has so many loop holes that quite frankly, it stinks to high heaven. But why spoil a good story with the truth

Could be right. The Marks effect plus an RNS this coming week will be a game changer

Require a 30% price hike to compensate for the weeks losses. Unlikely

Plus todays M&S report

Have seen Directors emoluments within "Office Costs" before now.

Very odd timing of such an important announcement and I wonder if there has been an announcement ****-up by their lawyers/Company Sec. The London SX opens for RNS's at around 7.00am and for security, they are often taken round by hand via staff or an agency I expect to see the RNS early Monday unless they have ****ed-up that

Tom 111. Sorry 2021 - but unsure if they have the capital to cover that. Had that been so, would have expected comments in the report to that effect. Potential large investors must surely be queuing at the prospect of investing herein.

The anticipated though temporary increase in costs next year close to the current approx price of $1700 per oz suggests plans for a massive capital input. I wonder if that capital will be provided by a potential partner or a placing ? By then, I imagine the gold price to be far far in advance of $1700, perhaps around $2500

Published late Friday night. Very positive so looking forward to market response on Monday morning.

£1m new shares which may well be to a trust ultimately owned by the directors. It goes on a lot. IMO

This week ?

Unclear how important Sierra Oncology is to the overall aim of Sareum scientists. Sierra seem to be wholly focused on one very rare type of blood disease and progress there has been excruciatingly slow. So unsure why Sareum would even give the Sierra news this publicity.

Doolinator. Seems like I have chosen an investment with sharp rude geezers like you. What happened to polite honest to goodness discussion ?

The RNS mentions Sierra with no explanation as to the corporate link. As a new investor here, anyone know what the Sierra link is and how SAR can benefit from this announcement